Natalizumab: A new hope for Crohn's Disease?

American Journal of Gastroenterology

Volumn 98, Issue 5, 2003, Pages 1197-1199

  Napierkowski, John ^a   Wong, Roy K H ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROHN DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; ENTERITIS; ERYTHEMA; EUROPE; HEADACHE; HUMAN; INFECTION; INFLUENZA; ISRAEL; MAJOR CLINICAL STUDY; NAUSEA; NOTE; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038746914     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(03)00237-5     Document Type: Note

References (10)

1. Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: Effects on education and employment in early adult life. Gut 1994;35:665-8.
2. Eckardt VF, Lesshafft C, Kanzler G, Bernhard G. Disability and health care use in patients with Crohn's disease. A spouse-control study. Am J Gastroenterol 1994;89:2157-62.
3. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;123:656.
4. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-9.
5. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
7. Hanauer S, Schaible T, DeWoody K, et al. Long-term follow up of patients treated with infliximab (anti-TNF alpha anti-body) in clinical trials. Gastroenterology 2000;18:A566 (abstract).
8. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
9. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
10. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68-72.